(R)-3-[(E)-3-(5-cyano-2-methoxy-phenyl)-acryloylamino]-4-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-butyric acid benzyl ester | 412015-68-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (R)-3-[(E)-3-(5-cyano-2-methoxy-phenyl)-acryloylamino]-4-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-butyric acid benzyl ester
• 英文别名: benzyl (3R)-3-[[(E)-3-(5-cyano-2-methoxyphenyl)prop-2-enoyl]amino]-4-[4-(4-fluorophenoxy)piperidin-1-yl]butanoate
• CAS: 412015-68-0
• 化学式: C₃₃H₃₄FN₃O₅
• 分子量: 571.648
• InChiKey: KQSABBACSPSEPS-RDMSYDOSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  42
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (R)-3-[(E)-3-(5-cyano-2-methoxy-phenyl)-acryloylamino]-4-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-butyric acid benzyl ester 、 sodium hydroxide 在 甲醇 、 水 、 乙醚 、 isopropyl alcohol chloroform 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以to afford (R)-3-[(E)-3-(5-cyano-2-methoxy-phenyl)-acryloylamino]-4-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-butyric acid的产率得到(R)-3-[(E)-3-(5-cyano-2-methoxy-phenyl)-acryloylamino]-4-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-butyric acid
  参考文献：
  名称：

  N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists

  摘要：

  化学式（I）的化合物以自由形式或盐形式存在，其中Ar1为苯基，被一个或多个取代基所取代，所述取代基选自卤素、氰基、硝基和C1-C8烷基，所述C1-C8烷基可选择被氰基或卤素所取代；Ar2为苯基，可选择不取代或被一个或多个取代基所取代，所述取代基选自卤素、氰基、羟基、硝基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基或C1-C8烷氧羰基；R1为C1-C8烷基，被羟基、C1-C8烷氧基、酰氧基、—N(R2)R3、卤素、羧基、C1-C8烷氧羰基、苯基-C1-C8烷氧羰基、-CON(R4)R5或一价环状有机基团所取代；R2和R3各自独立地为氢或C1-C8烷基，或R2为氢且R3为酰基或SO2R6，或R2和R3与它们所连接的氮原子一起表示一个5-或6-成员杂环基团；R4和R5各自独立地为氢、C1-C8烷基（可选择被羟基或苯基所取代），或苯基（可选择被C1-C8烷基、卤素、氰基或C1-C8烷氧基所取代），或R4和R5与它们所连接的氮原子一起表示一个5-或6-成员杂环基团；R6为C1-C8烷基、C1-C8卤代烷基或可选择被C1-C8烷基所取代的苯基；n为1、2、3或4。这些化合物可用作药物。

  公开号：

  US20040087621A1
• 作为产物：
  描述：

  3'-cyano-6'-methoxycinnamic acid 、 (R)-3-amino-4-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-butyric acid benzyl ester 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 在 三乙胺 作用下， 以 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 为溶剂， 生成 (R)-3-[(E)-3-(5-cyano-2-methoxy-phenyl)-acryloylamino]-4-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-butyric acid benzyl ester
  参考文献：
  名称：

  N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists

  摘要：

  式（I）的化合物，其自由或盐形式，其中Ar1为苯基，取代基选自卤素，氰基，硝基和C1-C8烷基，所述C1-C8烷基可以选择取代氰基或卤素；Ar2为苯基，可以选择不取代或取代基选自卤素，氰基，羟基，硝基，C1-C8烷基，C1-C8卤代烷基，C1-C8烷氧基或C1-C8烷氧羰基；R1为C1-C8烷基，取代基选自羟基，C1-C8烷氧基，酰氧基，-N（R2）R3，卤素，羧基，C1-C8烷氧羰基，苯基-C1-C8烷氧羰基，-CON（R4）R5或单价环状有机基团；R2和R3各自独立地为氢或C1-C8烷基，或R2为氢，R3为酰基或SO2R6，或R2和R3与它们所连接的氮原子一起表示5-或6-成员杂环基团；R4和R5各自独立地为氢，C1-C8烷基，可以选择取代羟基或苯基，或苯基，可以选择取代C1-C8烷基，卤素，氰基或C1-C8烷氧基，或R4和R5与它们所连接的氮原子一起表示5-或6-成员杂环基团；R6为C1-C8烷基，C1-C8卤代烷基或苯基，可以选择取代C1-C8烷基；n为1、2、3或4。该化合物可用于制药。

  公开号：

  US20040087621A1

文献信息

• N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR3-3 RECEPTOR ANTAGONISTS
  申请人：Novartis AG

  公开号：EP1330436A1

  公开（公告）日：2003-07-30
• US7034042B2
  申请人：——

  公开号：US7034042B2

  公开（公告）日：2006-04-25
• [EN] N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR33 RECEPTOR ANTAGONISTS<br/>[FR] AMIDES N-(4-ARYLOXYPIPERIDIN-1-YLALKYL)CINNAMIQUES UTILISES COMME ANTAGONISTES DU RECEPTEUR CCR33
  申请人：NOVARTIS AG

  公开号：WO2002030898A1

  公开（公告）日：2002-04-18

  Compounds of formula (I) in free or salt form, where Ar1 is phenyl substituted by one or more substituents selected from halogen, cyano, nitro, and C¿1?-C8-alkyl optionally substituted by cyano or halogen, Ar?2¿ is phenyl optionally which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C¿1?-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-alkoxycarbonyl, R?1 is C¿1-C8-alkyl substituted by hydroxy, C1-C8-alkoxy, acyloxy, -N(R2)R3, halogen, carboxy, C¿1?-C8-alkoxycarbonyl, phenyl- C1-C8-alkoxycarbonyl, -CON(R?4)R5¿ or by a monovalent cyclic organic group, R?2 and R3 ¿ are each independently hydrogen or C¿1?-C8-alkyl, or R?2¿ is hydrogen and R3 is acyl or SO¿2?R?6, or R2 and R3¿ together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R?4 and R5¿ are each independently hydrogen, C¿1?-C8-alkyl optionally substituted by hydroxy or phenyl, or phenyl optionally substituted by C1-C8-alkyl, halogen, cyano or C1-C8-alkoxy, or R?4 and R5¿ together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R6 is C1-C8-alkyl, C1-C8-haloalkyl, or phenyl optionally substituted by C1-C8-alkyl, and n is 1, 2, 3 or 4. The compounds are useful as pharmaceuticals.
• N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists
  申请人：——

  公开号：US20040087621A1

  公开（公告）日：2004-05-06

  Compounds of formula (I) in free or salt form, where Ar 1 is phenyl substituted by one or more substituents selected from halogen, cyano, nitro, and C 1 -C 8 -alkyl optionally substituted by cyano or halogen, Ar 2 is phenyl optionally which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C 1 -C 8 -alkyl, C 1 -C 8 -haloalkyl, C 1 -C 8 -alkoxy or C 1 -C 8 -alkoxycarbonyl, R 1 is C 1 -C 8 -alkyl substituted by hydroxy, C 1 -C 8 -alkoxy, acyloxy, —N(R 2 )R 3 , halogen, carboxy, C 1 -C 8 -alkoxycarbonyl, phenyl-C 1 -C 8 -alkoxycarbonyl, -CON(R 4 )R 5 or by a monovalent cyclic organic group, R 2 and R?3 are each independently hydrogen or C 1 -C 8 -alkyl, or R 2 is hydrogen and R 3 is acyl or SO 2 R 6 , or R 2 and R 3 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R 4 and R 5 are each independently hydrogen, C 1 -C 8 -alkyl optionally substituted by hydroxy or phenyl, or phenyl optionally substituted by C 1 -C 8 -alkyl, halogen, cyano or C 1 -C 8 -alkoxy, or R 4 and R 5 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R?6 is C 1 -C 8 -alkyl, C 1 -C 8 -haloalkyl, or phenyl optionally substituted by C 1 -C 8 -alkyl, and n is 1, 2, 3 or 4. The compounds are useful as pharmaceuticals.

  式（I）的化合物，其自由或盐形式，其中Ar1为苯基，取代基选自卤素，氰基，硝基和C1-C8烷基，所述C1-C8烷基可以选择取代氰基或卤素；Ar2为苯基，可以选择不取代或取代基选自卤素，氰基，羟基，硝基，C1-C8烷基，C1-C8卤代烷基，C1-C8烷氧基或C1-C8烷氧羰基；R1为C1-C8烷基，取代基选自羟基，C1-C8烷氧基，酰氧基，-N（R2）R3，卤素，羧基，C1-C8烷氧羰基，苯基-C1-C8烷氧羰基，-CON（R4）R5或单价环状有机基团；R2和R3各自独立地为氢或C1-C8烷基，或R2为氢，R3为酰基或SO2R6，或R2和R3与它们所连接的氮原子一起表示5-或6-成员杂环基团；R4和R5各自独立地为氢，C1-C8烷基，可以选择取代羟基或苯基，或苯基，可以选择取代C1-C8烷基，卤素，氰基或C1-C8烷氧基，或R4和R5与它们所连接的氮原子一起表示5-或6-成员杂环基团；R6为C1-C8烷基，C1-C8卤代烷基或苯基，可以选择取代C1-C8烷基；n为1、2、3或4。该化合物可用于制药。
• N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as CCR33 receptor antagonists
  申请人：Novartis AG

  公开号：US07034042B2

  公开（公告）日：2006-04-25

  Compounds of formula (I) in free or salt form, where Ar1 is phenyl substituted by one or more substituents selected from halogen, cyano, nitro, and C1–C8-alkyl optionally substituted by cyano or halogen, Ar2 is phenyl optionally which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C1–C8-alkyl, C1–C8-haloalkyl, C1–C8-alkoxy or C1–C8-alkoxycarbonyl, R1 is C1–C8-alkyl substituted by hydroxy, C1–C8-alkoxy, acyloxy, —N(R2)R3, halogen, carboxy, C1–C8-alkoxycarbonyl, phenyl-C1–C8-alkoxycarbonyl, —CON(R4)R5 or by a monovalent cyclic organic group, R2 and R?3 are each independently hydrogen or C1–C8-alkyl, or R2 is hydrogen and R3 is acyl or SO2R6, or R2 and R3 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R4 and R5 are each independently hydrogen, C1–C8-alkyl optionally substituted by hydroxy or phenyl, or phenyl optionally substituted by C1–C8-alkyl, halogen, cyano or C1–C8-alkoxy, or R4 and R5 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R?6 is C1–C8-alkyl, C1–C8-haloalkyl, or phenyl optionally substituted by C1–C8-alkyl, and n is 1, 2, 3 or 4. The compounds are useful as pharmaceuticals.

  化合物的公式(I)，可以是自由形式或盐形式，其中Ar1是苯基，被一个或多个来自卤素、氰基、硝基和C1-C8烷基（可选择性地被氰基或卤素取代）的取代基所取代，Ar2是苯基，可以是未取代或被一个或多个来自卤素、氰基、羟基、硝基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基或C1-C8烷氧羰基的取代基所取代，R1是被羟基、C1-C8烷氧基、酰氧、-N(R2)R3、卤素、羧基、C1-C8烷氧羰基、苯基-C1-C8烷氧羰基、-CON(R4)R5或单价环状有机基团所取代的C1-C8烷基，R2和R3各自独立地是氢或C1-C8烷基，或者R2是氢而R3是酰基或SO2R6，或者R2和R3与它们所连接的氮原子一起表示一个5或6成员的杂环基团，R4和R5各自独立地是氢、C1-C8烷基（可选择性地被羟基或苯基取代）或苯基（可选择性地被C1-C8烷基、卤素、氰基或C1-C8烷氧基取代），或者R4和R5与它们所连接的氮原子一起表示一个5或6成员的杂环基团，R6是C1-C8烷基、C1-C8卤代烷基或苯基（可选择性地被C1-C8烷基取代），n为1、2、3或4。这些化合物可用作药物。